Results 11 to 20 of about 1,643 (210)
Janus kinase inhibitors in immunoinflammatory rheumatic diseases
Терапевтический архив, 2022 Despite great advances in the diagnosis and treatment of immunoinflammatory rheumatic diseases, which have led to a significant improvement in the prognosis in many patients, the fundamental medical problems of this pathology the restoration of the ...
Evgeny L. Nasonov
doaj +1 more source
Janus kinase inhibitors in autoimmune bullous diseases
Frontiers in Immunology, 2023 Autoimmune bullous disease (AIBD) is a severe skin disorder caused by autoantibodies that target intercellular or cell-matrix adhesion proteins.
Dawei Huang +9 more
doaj +1 more source
Ruxolitinib found to cause eyelash growth: a case report
Journal of Medical Case Reports, 2017 Background Hypereosinophilic syndrome is a hematologic disorder in which the eosinophils proliferate. Oral Janus kinase inhibitors are known to be effective treating hypereosinophilic syndrome.
Julia Song +4 more
doaj +1 more source
The Emerging World of JAK Inhibitors
Nepal Journal of Dermatology, Venereology & LeprologyThe Janus Kinase inhibitors are a new emerging class of small molecules. These target the Janus Kinase proteins located on the cell membrane. Janus Kinase proteins regulate the cellular transcription of several proteins and act as mediators in several ...
Shraddha Uprety
doaj +3 more sources
Janus kinase inhibitors: jackpot or potluck?
Oncology Reviews, 2012 The reports of a unique mutation in the Janus kinase-2 gene (JAK2) in polycythemia vera by several independent groups in 2005 quickly spurred the development of the Janus kinase inhibitors.
Pavithran Keechilat +1 more
doaj +1 more source
Role of Janus Kinase Inhibitors in Therapy of Psoriasis [PDF]
Journal of Clinical Medicine, 2021 Janus kinases inhibitors are molecules that target Janus kinases—signal transducers and activators of transcription (JAK/STAT). They inhibit this intracellular signal pathway, blocking the gene transcription of crucial proinflammatory cytokines that play a central role in the pathogenesis of many inflammatory and autoimmune diseases, including ...
Sylwia Słuczanowska-Głąbowska +3 more
openaire +2 more sources
Hepatology, EarlyView., 2022 KAT7‐acetylated and cytoplasm‐translocated G‐protein GαS enhances IL‐6 effect and drives HCC progenitor cell progression. Abstract Background and Aims Hepatocarcinogenesis goes through HCC progenitor cells (HcPCs) to fully established HCC, and the mechanisms driving the development of HcPCs are still largely unknown.
Ye Zhou +15 more
wiley +1 more source
Hepatology, EarlyView., 2022 IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases Abstract Background and Aims Pruritus is associated with multiple liver diseases, particularly those with cholestasis, but the mechanism remains incompletely understood.
Jun Xu +20 more
wiley +1 more source
Hepatology, EarlyView., 2022 Mesenchymal stem cells subset, educated by TNF‐α, are involved to generate inflammatory microenvironment and promote hepatocarcinogenesis Abstract Background and Aims Increasing evidence suggests that mesenchymal stem cells (MSCs) home to injured local tissues and the tumor microenvironment in the liver.
Chen Zong +9 more
wiley +1 more source
Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis
Hepatology, EarlyView., 2022 Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres +21 more
wiley +1 more source